Literature DB >> 21766159

BMS309403 directly suppresses cardiac contractile function.

Christiane Look1, Ingo Morano, Monika Ehrhart-Bornstein, Stefan R Bornstein, Valéria Lamounier-Zepter.   

Abstract

BMS309403, a substance used as an inhibitor of adipocyte fatty acid-binding protein, has been suggested as a new therapeutic agent for treating type 2 diabetes mellitus and atherosclerosis; however, little is known about its possible side effects. The present study investigates the effects of BMS309403 on the cardiovascular system. We used isolated perfused heart preparations and single cardiomyocytes from adult rats for contractile analysis. The Ca(2+) sensitivity of the myofilaments was investigated by using porcine cardiac skinned muscle fibers. BMS309403 induced a negative effect on the contractility of isolated perfused hearts leading to heart arrest without interfering in the electrocardiographic activity, suggesting electromechanical dissociation. Experiments with isolated cardiomyocytes showed that BMS309403 had a direct biphasic inhibitory effect on cardiomyocyte contraction, at higher concentrations by attenuating Ca(2+) levels. This negative inotropic effect does not result from a direct effect on the myofilaments. BMS309403 has an acute cardiac depressant effect in vitro. The potential therapeutic applicability of this compound requires additional consideration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766159     DOI: 10.1007/s00210-011-0667-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization.

Authors:  B Binas; H Danneberg; J McWhir; L Mullins; A J Clark
Journal:  FASEB J       Date:  1999-05       Impact factor: 5.191

2.  Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.

Authors:  Fredik Lehmann; Saba Haile; Eva Axen; Carmen Medina; Jonas Uppenberg; Stefan Svensson; Thomas Lundbäck; Lena Rondahl; Tjeerd Barf
Journal:  Bioorg Med Chem Lett       Date:  2004-09-06       Impact factor: 2.823

Review 3.  Structural and functional features of different types of cytoplasmic fatty acid-binding proteins.

Authors:  J H Veerkamp; R A Peeters; R G Maatman
Journal:  Biochim Biophys Acta       Date:  1991-01-04

4.  Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity.

Authors:  Valéria Lamounier-Zepter; Monika Ehrhart-Bornstein; Peter Karczewski; Hannelore Haase; Stefan R Bornstein; Ingo Morano
Journal:  FASEB J       Date:  2006-08       Impact factor: 5.191

5.  Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

Authors:  Mary Yk Lee; Huiying Li; Yang Xiao; Zhiguang Zhou; Aimin Xu; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 6.  The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function.

Authors:  A V Hertzel; D A Bernlohr
Journal:  Trends Endocrinol Metab       Date:  2000-07       Impact factor: 12.015

7.  Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease.

Authors:  Valéria Lamounier-Zepter; Christiane Look; Julio Alvarez; Torsten Christ; Ursula Ravens; Wolf-Hagen Schunck; Monika Ehrhart-Bornstein; Stefan R Bornstein; Ingo Morano
Journal:  Circ Res       Date:  2009-07-16       Impact factor: 17.367

8.  Effects of mechanical uncouplers, diacetyl monoxime, and cytochalasin-D on the electrophysiology of perfused mouse hearts.

Authors:  Linda C Baker; Robert Wolk; Bum-Rak Choi; Simon Watkins; Patricia Plan; Anisha Shah; Guy Salama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-06-10       Impact factor: 4.733

9.  Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).

Authors:  Richard Sulsky; David R Magnin; Yanting Huang; Ligaya Simpkins; Prakash Taunk; Manorama Patel; Yeheng Zhu; Terry R Stouch; Donna Bassolino-Klimas; Rex Parker; Thomas Harrity; Robert Stoffel; David S Taylor; Thomas B Lavoie; Kevin Kish; Bruce L Jacobson; Steven Sheriff; Leonard P Adam; William R Ewing; Jeffrey A Robl
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

10.  Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA.

Authors:  C A Baxa; R S Sha; M K Buelt; A J Smith; V Matarese; L L Chinander; K L Boundy; D A Bernlohr
Journal:  Biochemistry       Date:  1989-10-31       Impact factor: 3.162

View more
  2 in total

1.  Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes.

Authors:  I Schlottmann; M Ehrhart-Bornstein; M Wabitsch; S R Bornstein; V Lamounier-Zepter
Journal:  Int J Obes (Lond)       Date:  2013-12-19       Impact factor: 5.095

2.  Adipocyte fatty acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects.

Authors:  A Baessler; V Lamounier-Zepter; S Fenk; C Strack; C Lahmann; T Loew; G Schmitz; M Blüher; S R Bornstein; M Fischer
Journal:  Nutr Diabetes       Date:  2014-02-10       Impact factor: 5.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.